Summary News Back
Rising awareness and media coverage of liver diseases, particularly PBC, including expert discussions and patient stories on various platforms.
Promising clinical trial results for new PBC treatments such as linerixibat, seladelpar (Livdelzi), and elafibranor (Iqirvo), showing improvements in symptoms like itch and fatigue.
Regulatory progress with multiple approvals and conditional authorizations of PBC treatments across Europe, the US, and the UK (e.g., Livdelzi, Iqirvo).
Ongoing research into the mechanisms and associated conditions of PBC, including links to lymphoma, systemic sclerosis, and gut microbiota.
Growing investment and milestone payments in the PBC drug development sector, reflecting commercial interest and expanding treatment options.
Studies highlighting the importance of early diagnosis, personalized treatment plans, and quality of life improvements for PBC patients.
Concerns over safety and effectiveness of existing treatments, with regulatory bodies declining or revoking approvals (e.g., Ocaliva).
Educational efforts through art, patient stories, and physician guidance to support awareness and understanding of rare liver diseases like PBC.
News Articles Back
14/11/2025 B.C. deal changes criteria for liver transplant eligibility for Indigenous people - Vernon Morning Star
13/11/2025 Defining Elafibranor’s Role in a New Era of PBC Management, With Cynthia Levy, MD - HCPLive
12/11/2025 Seladelpar Eases PBC-Related Itch for 30 Months - MedPage Today
12/11/2025 GLISTEN: Linerixibat Improves Biomarkers and Itch in Patients With PBC, With Andreas Kremer, MD, PhD, MHBA - HCPLive
12/11/2025 How Investors May Respond To Ipsen (ENXTPA:IPN) Positive Long-Term IQIRVO Data in PBC Trial - simplywall.st
12/11/2025 Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data - Liver Disease News
12/11/2025 Gilead Sciences (GILD): Assessing Valuation After Trodelvy Breast Cancer and Livdelzi PBC Data Updates - simplywall.st
11/11/2025 Long-Term Elafibranor Treatment Leads to Biochemical, Symptomatic Improvements in PBC - HCPLive
11/11/2025 Long-Term Efficacy and Symptom Relief With Elafibranor in PBC, With Andreas Kremer, MD, PhD - HCPLive
10/11/2025 Seladelpar’s Impact on Liver Stiffness Measurements in PBC, With Christopher Bowlus, MD - HCPLive
10/11/2025 Seladelpar Staves Off Liver Stiffness in PBC - Medscape
09/11/2025 Elafibranor Benefits Fatigue-Related Pathways Linked to Mitochondrial Function in PBC - HCPLive
09/11/2025 Seladelpar’s Role in the Post-Obeticholic Acid PBC Treatment Landscape, With Christopher Bowlus, MD - HCPLive
07/11/2025 Gilead reports long-term data supporting Livdelzi for PBC patients By Investing.com - Investing.com Nigeria
07/11/2025 Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression - Yahoo Finance
06/11/2025 Seladelpar Reduces Itching in Primary Biliary Cholangitis - Medscape
05/11/2025 VIDEO: Scoring tools may help identify nonresponders in primary biliary cholangitis - Healio
26/10/2025 Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies - Baishideng Publishing
22/10/2025 (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire
21/10/2025 LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Newswire Canada
14/10/2025 Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia - Nature
10/10/2025 Bezafibrate for primary biliary cholangitis: time to act on the evidence - Nature
09/10/2025 Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis - Cureus
07/10/2025 Linerixibat Reduces Itching in PBC - Medscape
03/10/2025 Primary Biliary Cholangitis (PBC) Workup: Approach Considerations, Laboratory Studies, Imaging Studies - Medscape eMedicine
03/10/2025 68Ga-FAPI-46 PET/CT in Primary Sclerosing Cholangitis and Suspected Cholangiocarcinoma - Journal of Nuclear Medicine
01/10/2025 PBC worst for life quality among autoimmune liver diseases: Study - Liver Disease News
19/09/2025 Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report - Cureus
15/09/2025 Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy - Frontiers
12/09/2025 Liver Disease Drug Pulled From the Market - MedPage Today
12/09/2025 Intercept pulls Ocaliva from US market; all clinical trials for PBC now on hold - Healio
11/09/2025 Ocaliva for PBC Withdrawn From US Market - Medscape
11/09/2025 Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold - Yahoo Finance
10/09/2025 Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma
10/09/2025 September's PBC Awareness Month raises support for a rare liver... - Liver Disease News
05/09/2025 Innate immunity of bile and cholangiocytes in primary biliary cholangitis - Frontiers
29/08/2025 Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis - Yahoo Finance
29/08/2025 Zydus Therapeutics announces positive topline results from EPICS-III Phase 2b/3 trial of Saroglitazar in Primary Biliary Cholangitis - Express Pharma
27/08/2025 Local Woman Launches Support Group For People With Primary Biliary Cholangitis - The Citizen Newspaper Group
26/08/2025 An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis | Scientific Reports - Nature
25/08/2025 Understanding PBC: Managing what Matters Most - Ipsen
09/08/2025 Early assessment of treatment response in primary biliary cholangitis: key to timely management - BMC Gastroenterology
03/08/2025 Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics - Frontiers
02/08/2025 Seladelpar Beneficial for Patients With Primary Biliary Cholangitis - Physician's Weekly
18/07/2025 The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial - BMC Gastroenterology
17/07/2025 GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights - Yahoo Finance
08/07/2025 Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation - Cureus
02/07/2025 Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis - Nature
30/06/2025 Treatment of pruritus in primary biliary cholangitis - Clínica FEHV
25/06/2025 EMA to review linerixibat for itch in primary biliary cholangitis - Liver Disease News
20/06/2025 Novel Therapies for Primary Biliary Cholangitis - Medscape Reference
12/06/2025 Primary biliary cholangitis and the narrowing gap towards optimal disease control - The Lancet
11/06/2025 T and B cell responses against Epstein–Barr virus in primary sclerosing cholangitis - Nature
04/06/2025 $2.27 Bn Primary Biliary Cholangitis Market Forecasts and - GlobeNewswire
04/06/2025 FDA Accepts GSKs NDA for First-in-Class IBAT Inhibitor Linerixibat to Treat Cholestatic Pruritus in Primary Biliary Cholangitis - Pharmaceutical Executive
02/06/2025 Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) - GSK
20/05/2025 Linerixibat Significantly Improves PBC-Related Cholestatic Pruritus in Adult Patients - Pharmacy Times
19/05/2025 Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine - Cureus
15/05/2025 Seladelpar Found Safe and Effective For Patients With PBC and Cirrhosis - Gastroenterology & Endoscopy News
14/05/2025 Livdelzi effective on primary biliary cholangitis, regardless of prior treatment - Liver Disease News
12/05/2025 Drug Slows Progression of Primary Sclerosing Cholangitis - Medscape
09/05/2025 Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy - Pharmaceutical Executive
09/05/2025 Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
08/05/2025 Iqirvo Shows Significant Fatigue Improvement in Patients with Primary Biliary Cholangitis After 52 Weeks in Phase III ELATIVE Trial - Applied Clinical Trials
08/05/2025 Oral IBAT Inhibitor Improves Cholestatic Itch in Primary Biliary Cholangitis - MedPage Today
07/05/2025 Bringing PBC Into Focus Through Art of Patient Stories - Gilead Sciences
06/05/2025 Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC - Ipsen
28/04/2025 Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis - Ipsen
25/04/2025 Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis - PMLiVE
23/04/2025 90% of People With This Rare Liver Disease Are Women—Meet the Patient Advocate Helping Empower Others - Flow Space
14/04/2025 Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization - Frontiers
09/04/2025 Scotland's NHS to cover Iqirvo for eligible adults with primary biliary cholangitis - Liver Disease News
08/04/2025 Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE
07/04/2025 The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease - Ipsen
07/04/2025 New vision for rare liver condition - HealthandCare.scot
26/03/2025 Living with Rare Liver Diseases: Unique challenges, Shared Experiences - Ipsen
21/03/2025 The Evolving Primary Biliary Cholangitis Landscape, with Craig Lammert, MD - HCPLive
07/03/2025 A Rare Case of Concurrent Primary Biliary Cholangitis and Sarcoidosis - Cureus
07/03/2025 Autoimmune Gastritis Complicated by Primary Biliary Cholangitis: A Report of Two Cases and Literature Review - Cureus
26/02/2025 Seladelpar approved to help treat primary biliary cholangitis in EU - Liver Disease News
26/02/2025 Guidelines on the diagnosis and management of primary biliary cholangitis - EurekAlert!
23/02/2025 Coexisting Primary Biliary Cholangitis and Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review - Cureus
20/02/2025 Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - Yahoo Finance
20/02/2025 EU okays Gilead's seladelpar for primary biliary cholangitis - FirstWord Pharma
13/02/2025 Elafibranor Increase Survival Primary Biliary Cholangitis Patients PBC - Gastroenterology & Endoscopy News
05/02/2025 Poor primary biliary cholangitis outcomes linked with two self-reactive antibodies - Liver Disease News
22/01/2025 Livdelzi approved in UK as PBC treatment for certain adults - Liver Disease News
20/01/2025 New treatment for primary biliary cholangitis - Clínica FEHV
20/01/2025 Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults - PMLiVE
10/01/2025 Exploration of Novel Metabolic Mechanisms Underlying Primary Biliary Cholangitis Using Hepatic Metabolomics, Lipidomics, and Proteomics Analysis - ACS Publications
10/01/2025 FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis - Pharmacy Times
08/01/2025 FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis - HCPLive
06/01/2025 A Rare Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome in a Male Patient - Cureus
02/01/2025 Serious liver injury being observed in patients without cirrhosis taki - fda.gov
28/12/2024 Development and external validation of an early prediction model to identify irresponsive patients and prognosis of UDCA treatment in primary biliary cholangitis - Nature
23/12/2024 Prompt Diagnosis, Management of Primary Biliary Cholangitis Key to Quality of Life - MedPage Today
13/12/2024 EMA Recommends Seladelpar for Primary Biliary Cholangitis - Medscape
11/12/2024 Sleep disorders common in PBC, linked to severe disease: Study - Liver Disease News
30/11/2024 Expanded Treatment Options for Primary Biliary Cholangitis Leave Open Questions - MedPage Today
26/11/2024 Answering Common Questions About Primary Biliary Cholangitis - Cleveland Clinic Health Essentials
